1. A clinical study of pyratrione, a tyrosine hydroxylase inhibitor, has been carried out in essential hypertension.

2. Out of thirty-nine patients who received pyratrione, twenty-eight showed a significant decrease in blood pressure.

This content is only available as a PDF.
You do not currently have access to this content.